209 related articles for article (PubMed ID: 32396617)
1. Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation.
Al Malki MM; Yang D; Labopin M; Afanasyev B; Angelucci E; Bashey A; Socié G; Karduss-Urueta A; Helbig G; Bornhauser M; Niittyvuopio R; Ganser A; Ciceri F; Brecht A; Koc Y; Bejanyan N; Ferraro F; Kebriaei P; Mokhtari S; Ghobadi A; Nakamura R; Forman SJ; Champlin R; Mohty M; Ciurea SO; Nagler A
Blood Adv; 2020 May; 4(9):2073-2083. PubMed ID: 32396617
[TBL] [Abstract][Full Text] [Related]
2. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.
Ciurea SO; Zhang MJ; Bacigalupo AA; Bashey A; Appelbaum FR; Aljitawi OS; Armand P; Antin JH; Chen J; Devine SM; Fowler DH; Luznik L; Nakamura R; O'Donnell PV; Perales MA; Pingali SR; Porter DL; Riches MR; Ringdén OT; Rocha V; Vij R; Weisdorf DJ; Champlin RE; Horowitz MM; Fuchs EJ; Eapen M
Blood; 2015 Aug; 126(8):1033-40. PubMed ID: 26130705
[TBL] [Abstract][Full Text] [Related]
3. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis.
Gooptu M; Romee R; St Martin A; Arora M; Al Malki M; Antin JH; Bredeson CN; Brunstein CG; Chhabra S; Fuchs EJ; Ghosh N; Grunwald MR; Kanakry CG; Kekre N; McGuirk JP; McNiece IK; Mehta RS; Mielcarek M; Milano F; Modi D; Reshef R; Solomon SR; Schroeder MA; Waller EK; Inamoto Y; Soiffer RJ; Eapen M
Blood; 2021 Jul; 138(3):273-282. PubMed ID: 34292325
[TBL] [Abstract][Full Text] [Related]
4. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
[TBL] [Abstract][Full Text] [Related]
5. Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS.
Marcoux C; Marin D; Ramdial J; AlAtrash G; Alousi AM; Oran B; Kebriaei P; Popat UR; Rezvani K; Champlin RE; Shpall EJ; Mehta RS
Am J Hematol; 2023 May; 98(5):712-719. PubMed ID: 36734029
[TBL] [Abstract][Full Text] [Related]
6. Post-Transplantation Cyclophosphamide-Based Haploidentical versus Matched Unrelated Donor Peripheral Blood Hematopoietic Stem Cell Transplantation Using Myeloablative Targeted Busulfan-Based Conditioning for Pediatric Acute Leukemia.
Hong KT; Park HJ; Kim BK; An HY; Choi JY; Kang HJ
Transplant Cell Ther; 2022 Apr; 28(4):195.e1-195.e7. PubMed ID: 35021131
[TBL] [Abstract][Full Text] [Related]
7. Impact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia.
Mehta RS; Ramdial J; Marin D; Alousi A; Kanakry CG; Champlin RE; Rezvani K; Shpall EJ; Page K; Gadalla SM; Kebriaei P; Weisdorf D
Transplant Cell Ther; 2023 Jun; 29(6):377.e1-377.e7. PubMed ID: 36990221
[TBL] [Abstract][Full Text] [Related]
8. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT.
Sanz J; Galimard JE; Labopin M; Afanasyev B; Sergeevich MI; Angelucci E; Kröger N; Koc Y; Ciceri F; Diez-Martin JL; Arat M; Sica S; Rovira M; Aljurf M; Tischer J; Savani B; Ruggeri A; Nagler A; Mohty M
J Hematol Oncol; 2021 May; 14(1):84. PubMed ID: 34049582
[TBL] [Abstract][Full Text] [Related]
10. A Calcineurin Inhibitor Free Graft Versus Host Disease Prophylaxis for Patients Undergoing Matched Related and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant.
Iqbal M; Nieto FAM; Brannick KM; Li Z; Murthy H; Foran J; Roy V; Kharfan-Dabaja MA; Ayala E
Transplant Cell Ther; 2023 May; 29(5):327.e1-327.e9. PubMed ID: 36758832
[TBL] [Abstract][Full Text] [Related]
11. Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas.
Mussetti A; Kanate AS; Wang T; He M; Hamadani M; Finel H; Boumendil A; Glass B; Castagna L; Dominietto A; McGuirk J; Blaise D; Gülbas Z; Diez-Martin J; Marsh SGE; Paczesny S; Gadalla SM; Dreger P; Zhang MJ; Spellman SR; Lee SJ; Bolon YT; Sureda A
Transplant Cell Ther; 2023 Mar; 29(3):184.e1-184.e9. PubMed ID: 36577482
[TBL] [Abstract][Full Text] [Related]
12. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.
Dreger P; Sureda A; Ahn KW; Eapen M; Litovich C; Finel H; Boumendil A; Gopal A; Herrera AF; Schmid C; Diez-Martin JL; Fuchs E; Bolaños-Meade J; Gooptu M; Al Malki MM; Castagna L; Ciurea SO; Dominietto A; Blaise D; Ciceri F; Tischer J; Corradini P; Montoto S; Robinson S; Gülbas Z; Hamadani M
Blood Adv; 2019 Feb; 3(3):360-369. PubMed ID: 30723110
[TBL] [Abstract][Full Text] [Related]
13. High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation.
Pedraza A; Jorge S; Suárez-Lledó M; Pereira A; Gutiérrez-García G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
Transplant Cell Ther; 2021 Jul; 27(7):619.e1-619.e8. PubMed ID: 33895157
[TBL] [Abstract][Full Text] [Related]
14. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.
Wieduwilt MJ; Metheny L; Zhang MJ; Wang HL; Estrada-Merly N; Marks DI; Al-Homsi AS; Muffly L; Chao N; Rizzieri D; Gale RP; Gadalla SM; Cairo M; Mussetti A; Gore S; Bhatt VR; Patel SS; Michelis FV; Inamoto Y; Badawy SM; Copelan E; Palmisiano N; Kharfan-Dabaja MA; Lazarus HM; Ganguly S; Bredeson C; Diaz Perez MA; Cassaday R; Savani BN; Ballen K; Martino R; Wirk B; Bacher U; Aljurf M; Bashey A; Murthy HS; Yared JA; Aldoss I; Farhadfar N; Liu H; Abdel-Azim H; Waller EK; Solh M; Seftel MD; van der Poel M; Grunwald MR; Liesveld JL; Kamble RT; McGuirk J; Munker R; Cahn JY; Lee JW; Freytes CO; Krem MM; Winestone LE; Gergis U; Nathan S; Olsson RF; Verdonck LF; Sharma A; Ringdén O; Friend BD; Cerny J; Choe H; Chhabra S; Nishihori T; Seo S; George B; Baxter-Lowe LA; Hildebrandt GC; de Lima M; Litzow M; Kebriaei P; Hourigan CS; Abid MB; Weisdorf DJ; Saber W
Blood Adv; 2022 Jan; 6(1):339-357. PubMed ID: 34547770
[TBL] [Abstract][Full Text] [Related]
15. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO
Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668
[TBL] [Abstract][Full Text] [Related]
16. Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type.
Mehta RS; Marin D; Alousi A; Kanakry CG; Champlin RE; Rezvani K; Shpall EJ; Page K; Gadalla SM; Weisdorf D; Kebriaei P
Blood Adv; 2023 Apr; 7(8):1594-1603. PubMed ID: 36630564
[TBL] [Abstract][Full Text] [Related]
17. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
18. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
[TBL] [Abstract][Full Text] [Related]
19. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors.
Brissot E; Labopin M; Moiseev I; Cornelissen JJ; Meijer E; Van Gorkom G; Rovira M; Ciceri F; Griskevicius L; Blaise D; Forcade E; Mistrik M; Mielke S; Bulabois CE; Niittyvuopio R; Deconinck E; Ruggeri A; Sanz J; Spyridonidis A; Savani B; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2020 Jul; 13(1):87. PubMed ID: 32620146
[TBL] [Abstract][Full Text] [Related]
20. Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
Moiseev IS; Pirogova OV; Alyanski AL; Babenko EV; Gindina TL; Darskaya EI; Slesarchuk OA; Bondarenko SN; Afanasyev BV
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1037-1042. PubMed ID: 26970381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
